Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: To understand patient preferences for once‐daily oral versus once‐weekly injectable type 2 diabetes mellitus (T2DM) medication administration profiles, and reasons for their preferences. Materials and methods: The REVISE study, a cross‐sectional online survey of 600 participants with T2DM (United Kingdom, n = 300; United States, n = 300), elicited general preferences for once‐daily oral versus once‐weekly injectable diabetes medications, and reasons for the preference. Participants then viewed two videos describing the administration procedures for injectable dulaglutide and oral semaglutide, based on the product instructions for use. Thereafter, participants indicated their preference for a once‐weekly injectable or a once‐daily oral medication based on the video descriptions. Participants who switched preferences were asked to identify the reasons influencing their decision. Results: The participants were predominantly male (n = 349; 58.2%), with a mean (SD) age of 64 (11.3) years. Nearly all (n = 557; 92.8%) were taking an oral T2DM medication, and 158 (26.3%) were using an injectable. Initially, 76.5% (n = 459; 95% confidence interval [CI] 73.1–79.9) preferred a once‐daily oral and 23.5% a once‐weekly injectable (n = 141; 95% CI 20.1–26.9; P < 0.0001). After viewing the videos describing the product‐specific administration, the proportions of participants preferring each option were not statistically different (oral semaglutide administration description (n = 315; 52.5%; 95% CI 48.5–56.5; dulaglutide administration description (n = 285; 47.5%; 95% CI 43.5–51.5; NS, P = 0.2207). The most common reason for switching preferences was the timing and steps of administration. Conclusion: Several treatment‐related characteristics, including route, frequency and complexity of the treatment, play a role in patients' preferences for T2DM treatments and should be considered during treatment selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192 · cited 1×
“First-line T2DM therapy is metformin, along with lifestyle modifications, such as diet, exercise, and weight management.(3) For patients who are unable to control blood glucose levels with metformin therapy and lifestyle changes, physicians may consider pharmacological treatment such as a glucagon-like peptide 1 recep…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1168291 · Cited by 511
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 2×
“0%).(16) However, to date, no known published research has directly compared a once-daily oral medication to once-weekly injectable administration.”
Background
Research works printed but not linked: 10
- 10.1016/j.jval.2019.11.009 · doi:10.1016/j.jval.2019.11.009
- 10.1185/03007995.2011.625404 · DOI
- 10.1177/0145721706288182 · DOI
- 10.1007/s40271-017-0225-0 · DOI
- 10.1185/03007995.2015.1117433 · DOI · Paper page
- 10.1177/2042018815595584 · DOI
- 10.2147/PPA.S14477 · DOI · Paper page
- 10.1186/s12913-015-1174-8 · DOI · Paper page
- 10.1016/j.clinthera.2016.05.009 · DOI · Paper page
- 10.1007/s40258-013-0023-3 · DOI · Paper page
Cited by
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2500969 · Cited by 142
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Metadata
- Authors
- Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-12-13
- Volume
- 23
- Issue
- 2
- Pages
- 508-519
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3095909321
- Cited by
- 88
- References
- 5
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study. https://app.cochat.ai/papers/10.1111/dom.14244
- The paper
- Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021). Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14244
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.